Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=280 To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
Skin Care
Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants
N/A N=81 SPT for Sensitization of Collagen Dressing
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
Phase 3 N=39 Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth
Surgery
Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
Phase 1 N=234 A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
Healthy
Primary: Observed Sensitization — 0; 0; 0 Participants with Observed Sensitization
N/A N=240 To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 3 — 0; 0 Score on scale
Phase 2 N=48 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
N/A N=58 Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
Erythema · Sensitisation
Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants
Phase 3 N=235 Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
N/A N=209 Repeated Insult Patch Test of Personal Lubricants
Erythema · Edema
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0 participants
Phase 2 N=50 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
N/A N=90 A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin
Skin Care
Primary: Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use — 3; 0…
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Dermal Irritation
Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants
Phase 4 N=206 Neo-Synalar Modified 48 Hour Patch Test
Allergy
Primary: Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS) — 0 percentage of patients w allergic rxn
N/A N=36 Patch Test of Benzalkonium Chloride Disinfectant Spray
Wound Healing
Primary: Proportion of Participants With Skin Irritation Scores at 24 Hours — 75.0; 91.7; 94.4; 94.4 Percentage of participants
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
N/A N=40 To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
Skin Care
Primary: Frequency of Dermal Response Score at 15-30 Minutes Post Patch Removal — 0; 0; 0; 0 Participants
N/A N=222 Human Repeat Insult Patch Test to Evaluate Personal Lubricants
Erythema · Edema
Primary: Number of Patients That Showed Sensitization Reaction to the Test Material at Challenge — 0 Participants
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
N/A N=118 Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants
N/A N=124 Safety Study of a Sensitive Sensual Touch and Personal Lubricant
Inadequate Lubrication
Primary: Number of Participants With Physical Irritation Scores — 61; 61; 1; 0 Participants
Phase 1 N=58 Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Photoallergy
Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
Phase 2 N=201 Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
Immune System Diseases
Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants